Abstract
Background/Aim: The use of proton pump inhibitors (PPIs) is known to lead to hypergastrinemia; however, the data in patients with atrophic gastritis is still lacking. The aim of this study was to investigate the effects of long-term PPIs use on the gastrin levels in patients with atrophic gastritis and to determine factors affecting hypergastrinemia in long-term users of PPIs. Methods: Serum Helicobacter pylori IgG, gastrin and pepsinogen levels were measured. Atrophic gastritis was assessed by upper gastrointestinal endoscopies based on the Kimura-Takemoto classification and pepsinogen levels. CYP2C19 polymorphisms were assessed using DNA extracted from peripheral blood. Results: A total number of 382 patients (275 men and 107 women) were enrolled. Median serum gastrin levels were higher in PPI users than in non- users (234 vs. 113 pg/mL, p < 0.001) and in women than in men (252 vs. 155 pg/mL, p = 0.006). Gastrin levels were significantly associated with corpus atrophy only in the subgroup of non-users of PPIs. Multivariate analysis revealed that hypergastrinemia (over 150 pg/mL) was significantly associated with PPI use (OR 5.30; 95% CI 3.32–8.47), women (OR 2.22; 95% CI 1.33–3.72) and corpus atrophy (OR 1.82; 95% CI 1.14–2.90). Conclusion: PPI use, women and corpus atrophy were risk factors for hypergastrinemia. Gender, but not corpus atrophy, affected the gastrin levels in long-term users of PPIs.
Journal Section:
Original Paper
References
1.
Schubert ML, Peura DA: Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842–1860.
[PubMed]
2.
Schmitz F, Göke MN, Otte JM, Schrader H, Reimann B, Kruse ML, Siegel EG, Peters J, Herzig KH, Fölsch UR, Schmidt WE: Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa. Regul Pept 2001; 102: 101–110.
[PubMed]
3.
Burkitt MD, Varro A, Pritchard DM: Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol 2009; 15: 1–16.
[PubMed]
4.
Walsh JH: Role of gastrin as a trophic hormone. Digestion 1990; 47: 11–16.
[PubMed]
5.
Mattsson H, Havu N, Bräutigam J, Carlsson K, Lundell L, Carlsson E: Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991; 100: 311–319.
[PubMed]
6.
Smith AM, Watson SA: Review article: gastrin and colorectal cancer. Aliment Pharmacol Ther 2000; 14: 1231–1247.
[PubMed]
7.
Ho AC, Horton KM, Fishman EK: Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings. Clin Imaging 2000; 24: 200–203.
[PubMed]
8.
Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J: Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115: 275–280.
[PubMed]
9.
McGuigan JE, Trudeau WL: Serum and tissue gastrin concentrations in patients with carcinoma of the stomach. Gastroenterology 1973; 64: 22–25.
[PubMed]
10.
Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT; Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755–760.
[PubMed]
11.
Jensen RT: Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4–19.
[PubMed]
12.
Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M: Hypergastrinemia. Gastroenterol Rep (Oxf) 2015; 3: 201–208.
13.
Maconi G, Lazzaroni M, Sangaletti O, Bargiggia S, Vago L, Bianchi Porro G: Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am J Gastroenterol 1997; 92: 1844–1848.
[PubMed]
14.
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ: Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649–663.
[PubMed]
15.
Yagita M: Effect of histamine H2-antagonists on serum gastrin levels in gastric lumen-perfused rats. J UOEH 1988; 10: 189–201.
[PubMed]
16.
Shimoyama T, Chinda D, Matsuzaka M, Takahashi I, Nakaji S, Fukuda S: Decrease of serum level of gastrin in healthy Japanese adults by the change of Helicobacter pylori infection. J Gastroenterol Hepatol 2014; 29: 25–28.
[PubMed]
17.
Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA: Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587–1600.
[PubMed]
18.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel: Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–664.
[PubMed]
19.
Shimura S, Hamamoto N, Yoshino N, Kushiyama Y, Fujishiro H, Komazawa Y, Furuta K, Ishihara S, Adachi K, Kinoshita Y: Diarrhea caused by proton pump inhibitor administration: comparisons among lansoprazole, rabeprazole, and omeprazole. Curr Ther Res Clin Exp 2012; 73: 112–120.
[PubMed]
20.
Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G; Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412–420.
[PubMed]
21.
Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi T, Fujita M, Okada A: The effects of switching to vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion 2017; 96: 52–59.
[PubMed]
22.
Okuyama M, Nakahara K, Iwakura N, Hasegawa T, Oyama M, Inoue A, Ishizu H, Satoh H, Fujiwara Y: Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor-refractory gastroesophageal reflux disease. Digestion 2017; 95: 281–287.
[PubMed]
23.
Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, Iwakiri K: Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017; 95: 156–161.
[PubMed]
24.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K: Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43: 240–251.
[PubMed]
25.
Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19: 25–35.
26.
Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, Nakano S, Higuchi S: Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647–653.
[PubMed]
27.
Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552–561.
[PubMed]
28.
Katsuki H, Nakamura C, Arimori K: Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997; 52: 391–396.
[PubMed]
29.
Lundell L, Hatlebakk J, Galmiche JP, Attwood SE, Ell C, Fiocca R, Persson T, Nagy P, Eklund S, Lind T; Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial. Curr Med Res Opin 2015; 31: 65–73.
[PubMed]
30.
Kimura K, Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 1: 87–97.
31.
Ueda J, Okuda M, Nishiyama T, Lin Y, Fukuda Y, Kikuchi S: Diagnostic accuracy of the E-plate serum antibody test kit in detecting Helicobacter pylori infection among Japanese children. J Epidemiol 2014; 24: 47–51.
[PubMed]
32.
Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT: Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85: 295–330.
[PubMed]
33.
Miki K: Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels – “ABC method”. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 405–414.
[PubMed]
34.
Feldman M, Richardson CT, Walsh JH: Sex-related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest 1983; 71: 715–720.
[PubMed]
35.
Wu SV, Giraud A, Mogard M, Sumii K, Walsh JH: Effects of inhibition of gastric secretion on antral gastrin and somatostatin gene expression in rats. Am J Physiol 1990; 258: 788–793.
[PubMed]
36.
Neonakis E, Vassilakis JS, Xynos E, Kittas C, Androulakis G: Fundic, antral and pancreatic D-cell population changes following oophorectomy and sex hormone administration in guinea pigs. Experimental immunocytochemical study. Eur Surg Res 1988; 20: 144–148.
[PubMed]
37.
Shih GL, Brensinger C, Katzka DA, Metz DC: Influence of age and gender on gastric acid secretion as estimated by integrated acidity in patients referred for 24-hour ambulatory pH monitoring. Am J Gastroenterol 2003; 98: 1713–1718.
[PubMed]
38.
Lahner E, Centanni M, Agnello G, Gargano L, Vannella L, Iannoni C, Delle Fave G, Annibale B: Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med 2008; 121: 136–141.
[PubMed]
39.
Cabrera de León A, Almeida González D, Almeida AA, González Hernández A, Carretero Pérez M, Rodríguez Pérez Mdel C, Guillén VG, Brito Díaz B: Factors associated with parietal cell autoantibodies in the general population. Immunol Lett 2012; 147: 63–66.
[PubMed]
40.
Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, Evans DJ Jr: Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522–525.
[PubMed]
41.
Tokushima H, Tamura H, Murakawa M, Matsumura O, Itakura Y, Itoyama S, Mitarai T, Isoda K: Eradication of Helicobacter pylori restores elevation of serum gastrin concentrations in patients with end-stage renal disease. Intern Med 1998; 37: 435–439.
[PubMed]
42.
Eren M, Çolak Ö, Işıksoy S, Yavuz A: Effect of H. pylori infection on gastrin, ghrelin, motilin, and gastroesophageal reflux. Turk J Gastroenterol 2015; 26: 367–372.
[PubMed]
43.
Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, Tatsuta M, Graham DY: Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005; 115: 463–469.
[PubMed]
44.
Schubert ML: Gastric secretion. Curr Opin Gastroenterol 2014; 30: 578–582.
[PubMed]
45.
Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta Tl: Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013; 38: 1129–1137.
[PubMed]
46.
Carmel R: Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 1996; 156: 1097–1100.
[PubMed]
47.
Tari A, Hamada M, Kamiyasu T, Sumii K, Haruma K, Inoue M, Kishimoto S, Kajiyama G, Walsh JH: Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients. Dig Dis Sci 1997; 42: 1741–1746.
[PubMed]
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.
